Dosing

KISQALI provides convenient dosing with either an AI or fulvestrant. *⁽¹⁾

KISQALI has a once-daily dosing regimen: ⁽¹⁾

The recommended starting dose is 600 mg (3 x 200 mg tablets)
KISQALI can be taken with or without food. Patients should be encouraged to take their dose at approximately the same time each day, preferably in the morning

28-day dosing schedule illustrating KISQALI 600mg (3 tablets/day) taken for 21 consecutive days followed by 7 days off, combined with continuous AI or Fulvestrant. Fulvestrant is administered on Days 1 and 15 of Cycle 1, then monthly. Diagram shows daily tablet intake and injection timeline.

* KISQALI is prescribed in combination with an AI or fulvestrant in pre-, peri- and postmenopausal women. In pre- or perimenopausal women, KISQALI should be prescribed in combination with AI or fulvestrant alongside an LHRH agonist. KISQALI should not be co-administered with tamoxifen.

Please refer to the respective Summary of Product Characteristics for more information on dosing. ⁽¹⁾
^† Continue treatment as long as the patient is deriving clinical benefit from therapy or until unacceptable toxicity occurs. ⁽¹⁾

Abbreviations
AI, aromatase inhibitor; LHRH, luteinising hormone releasing hormone.

References

KISQALI (ribociclib). Summary of Product Characteristics.

Monitoring and dosing

Dosing

KISQALI provides convenient dosing with either an AI or fulvestrant. *(1)

KISQALI provides convenient dosing with either an AI or fulvestrant. *⁽¹⁾